RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company, announced it has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in an oral poster presentation at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10.
|Oral Poster Presentation Details:|
|Poster Title:||Aldosterone Synthase Inhibition with Lorundrostat for the Treatment of Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial|
|Presenter Name:||Luke Laffin, M.D., cardiologist, Cleveland Clinic’s Heart, Vascular & Thoracic Institute, and lead investigator of the Target-HTN trial|
|Date/Time:||Sunday, September 10 at 7:45 a.m. ET|
|Session Title:||19.C Insight from the Late Breaking Clinical Trials|